BI-1569912

BI-1569912
Clinical data
Other namesBI1569912
Routes of
administration		Oral[1]
Drug classNR2B subunit-containing NMDA receptor negative allosteric modulator

BI-1569912 is a selective negative allosteric modulator of NR2B-containing NMDA receptors.[1] It is being developed by Boehringer Ingelheim to treat major depressive disorder.[1][2][3][4][5][6] As of May 2025, it is in phase 2 clinical trials.[7]

See also

References

  1. 1 2 3 "BI 1569912". AdisInsight. 27 May 2025. Retrieved 5 June 2026.
  2. ↑ Just, Stefan; Ceci, Angelo; Ferger, Boris; Draheim, Henning; Giovannini, Riccardo; Rosenbrock, Holger; Dorner-Ciossek, Cornelia (May 2022). "P376. Preclinical Pharmacological Characterization of the Selective NR2b Negative Allosteric Modulator BI 1569912 With Potential to Treat MDD". Biological Psychiatry. 91 (9): S239. doi:10.1016/j.biopsych.2022.02.612.
  3. ↑ Chen, Xiaowei; De Smedt, Heidi; Drevets, Wayne; Chen, Guang (May 2022). "P287. Data-Derived Subtypes of Treatment-Resistant Depression and Their Biomarker Correlates – A Pilot Study". Biological Psychiatry. 91 (9): S203–S204. doi:10.1016/j.biopsych.2022.02.523.
  4. ↑ Brady, Linda S.; Lisanby, Sarah H.; Gordon, Joshua A. (2023). "New directions in psychiatric drug development: promising therapeutics in the pipeline". Expert Opinion on Drug Discovery. 18 (8): 835–850. doi:10.1080/17460441.2023.2224555.
  5. ↑ Schultheis, Christian; Hoch, Anja; Just, Stefan; Plano, Andrea (May 2022). "P285. Pharmacological Effects of the Novel NR2B Modulator Bi 1569912 on Electroencephalography and Eye-Tracking in a Phase I Study". Biological Psychiatry. 91 (9): S203. doi:10.1016/j.biopsych.2022.02.521.
  6. ↑ Desch, Michael; Huennemeyer, Andreas; Süssmuth, Sigurd D. (2022). "P712. Safety, Tolerability, and Pharmacokinetics of Single Rising Doses of Bi 1569912 in Healthy Males: A Phase I Study". Biological Psychiatry. 91 (9): S379. doi:10.1016/j.biopsych.2022.02.949.
  7. ↑ "BI-1569912 by Boehringer Ingelheim International for Major Depressive Disorder: Likelihood of Approval". Pharmaceutical Technology. 25 February 2023. Retrieved 4 November 2023.
This page is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.